Edison Issues Report on Percheron Therapeutics (PER)
London, United Kingdom--(Newsfile Corp. - November 27, 2025) - Edison issues report on Percheron Therapeutics (ASX: PER) We have refreshed our investment case for Percheron as the company heads into CY26 with a clearly defined Phase II plan for HMBD-002, backed by positive Phase I data and a strengthened management team. Our model now reflects the likely Phase II basket design, comprising exploratory and subsequent expansion cohorts, along with refined assumptions on study size, sequenc
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-27 3:16 AM EST | Edison Group
MyndTec Inc. Announces Resignation of Director
Mississauga, Ontario--(Newsfile Corp. - November 26, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, today announced that P. Harvey Griggs has resigned from the Company's Board of Directors, effective November 26, 2025, for personal reasons to focus on his health. Dr. Griggs served as a director of MyndTec for six years and was an early investor in the Company. "On behalf of the Boa
Technology, Healthcare and Hospitals, Health
2025-11-26 5:30 PM EST | MyndTec Inc.
TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax, Truvia, Diamond and more Strategic agreement supports TempraMed's global shift from online B2C to major pharmacy networks and B2B medical payers Distribution to over 2,500 outlets including pharmacy chains, supermarkets, HMOs and independent pha
Technology, Biotechnology, Pharmaceuticals, Health
2025-11-26 4:51 PM EST | TempraMed Technologies Ltd
Hemostemix Starts its Roll-up of Cardiology Practices, Acquiring its First Two
Calgary, Alberta--(Newsfile Corp. - November 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), is pleased to announce a binding Letter of Intent for the acquisition of the first two cardiology practices under the Company's clinic roll-up and commercialization strategy. The practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two of the Dominican Republic's most respected interventional cardiologists, will be acquired by Hemostemi
Biotechnology, Pharmaceuticals, Health
2025-11-26 4:21 PM EST | Hemostemix Inc.
DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx(TM) Red Eye Diagnostic Test
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing cutting-edge point-of-care eye diagnostic solutions, is pleased to announce its scientific collaboration with the renowned LV Prasad Eye Institute (LVPEI) in Hyderabad, India. The partnership supports the clinical validation of TeaRx™, the Company's next-generation Red Eye diagnostic test. DiagnosTear is currently dev
2025-11-26 4:15 PM EST | DiagnosTear Technologies Inc.
Optimi Health to Supply MDMA to MAPS Israel's Clinical Trial for Trauma-Related PTSD
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical-grade psychedelics, including MDMA and naturally derived psilocybin, has been selected to supply the MDMA capsules for MAPS Israel's Healing October 7th project, which includes a clinical trial for Post-Traumatic Stress Disorder (PTSD) that has received formal approval from the Israeli
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-11-26 7:00 AM EST | Optimi Health Corp.
PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") and BioGene Therapeutics Inc. ("BioGene"), are pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025, October 10, 2025, Oc
Biotechnology, Pharmaceuticals, Health
2025-11-26 7:00 AM EST | PreveCeutical Medical Inc.
Edison Issues Report on Faraday Future Intelligent Electric (FFAI)
London, United Kingdom--(Newsfile Corp. - November 26, 2025) - Edison issues report on Faraday Future Intelligent Electric (NASDAQ: FFAI). Faraday Future Intelligent Electric (NASDAQ: FFAI) is expanding its strategy beyond being a luxury electric vehicle (EV) pioneer to include an asset-light, partnership-led production model. Its vehicle differentiation is based on an AI-powered mobility ecosystem using proprietary software. Its current focus is on product delivery and sales execution,
Banking / Financial Services, Computer Hardware, Computer Software, Health
2025-11-26 5:18 AM EST | Edison Group
Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today the completion of enrollment in its ongoing Phase 1b clinical trial of INTASYL siRNA PH-762. In connection with completing enrollment, Phio continues to treat additional patients in the fifth co
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-25 11:30 AM EST | Phio Pharmaceuticals Corp.
HRAL Announces Preparation of First Shipment of a Small House Destined for Jamaica in Hopes of a Much Larger Order to Aid the Homeless
Miami, Florida--(Newsfile Corp. - November 25, 2025) - Hear At Last (OTCID: HRAL) is pleased to announce that the first order from its recently secured 100-unit contract is now being prepared for shipment to Jamaica. This milestone marks a significant step in the company's continued international expansion and underscores the growing demand for HRAL's innovative solutions within the Caribbean market. The initial shipment represents the beginning of a multi-phase fulfillment
Household / Consumer / Cosmetics, Health
2025-11-25 8:00 AM EST | Hear AtLast Holdings, Inc
Aleen Inc. Announces Development of Personal Account for Wellness Data Management
Toronto, Ontario--(Newsfile Corp. - November 25, 2025) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, makes a landmark, forward-driving announcement - taking a decisive leap forward and unveiling the development of a personal account system that redefines how individuals interact with their wellness data. Following the insights gained during the Smart Analytics concept testing, this innovation marks a new era of personalization, security, and empowerment in the d
2025-11-25 8:00 AM EST | Aleen Inc.
Glow Lifetech Reports Record Q3 2025 Financial Results; 193% YoY Revenue Growth and Achieves First Positive Cash Flow from Operations
Toronto, Ontario--(Newsfile Corp. - November 25, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the third quarter ended September 30, 2025 ("Q3 2025"). In Q3 2025, Glow delivered strong revenue growth, sustained high gross margins, and achieved its first-ever quarter of positive cash flow from operations, reflecting continued commercial momentum and progress toward sustainable profitabili
2025-11-25 7:30 AM EST | Glow Lifetech Corp.
Safe Supply Secures Exclusive Canadian Rights to Healthy Sprays' Proprietary GLP-1 Delivery Technology; Announces Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - November 24, 2025) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in the health, safety and rapid response technologies, is pleased to announce it has entered into an Exclusive Territory License and Commercial Agreement (the "Licensing Agreement") with Healthy Sprays LLC ("Healthy Sprays"), granting Safe Supply the exclusive Canadian rights to distribute th
2025-11-24 9:05 AM EST | Safe Supply Streaming Co Ltd.
ADIA Nutrition Submits Patent-Pending Autism Protocol for Independent IRB Review - Clinical Study Launch Nears
Winter Park, Florida--(Newsfile Corp. - November 24, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) announced today that, following the independent Institutional Review Board's (IRB) acceptance of its initial draft protocol and invitation to submit a final version, the company has now officially delivered the complete, Patent-Pending regenerative protocol for pediatric Autism Spectrum Disorder (ASD) for full review and potential acceptance of oversight. This submission represents a pivotal
Healthcare and Hospitals, Health
2025-11-24 8:00 AM EST | Adia Nutrition Inc.
Functional Brands Issues Letter to Shareholders
Lake Oswego, Oregon--(Newsfile Corp. - November 24, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a leading innovator in wellness and performance products, issued the following letter from Eric Gripentrog, Chief Executive Officer. Dear Valued Shareholders, It is with great pride and enthusiasm that I write to you at this pivotal moment for our company. As the CEO of Functional Brands, I want to share our story, reaffirm our vision and values, and set the tone for the next chapter
Household / Consumer / Cosmetics, Health
2025-11-24 8:00 AM EST | Functional Brands Inc.
NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates
Expanded CONNECT SCI Study data demonstrated unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic spinal cord injury Completed a U.S. Food and Drug Administration (FDA) Type C meeting in September; FDA confirmed that multiple regulatory routes are available to support approval of NVG-291 as the first pharmacologic treatment for spinal cord injury Completed a US$1
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:05 AM EST | NervGen Pharma Corp.
NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury
Week 16 follow-up data, coupled with blinded exit interviews conducted up to 364 days after the study period, confirm durable and wide-ranging upper and lower-body improvements compared to placebo Participant-reported outcomes highlight substantial improvements in bladder control and muscle spasticity compared to placebo Statistically significant reduction of hyperactive reticulospinal signaling in upper and lower limbs
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-11-24 7:00 AM EST | NervGen Pharma Corp.
Cheelcare Receives "Compliant" Rating from Health Canada Following Routine Inspection
Markham, Ontario--(Newsfile Corp. - November 24, 2025) - Cheelcare Inc. (TSXV: CHER) ("Cheelcare" or the "Company"), a Canadian leader in assistive mobility devices, has received a "Compliant" rating from Health Canada, following a routine regulatory inspection conducted between October 22 and November 3, 2025. The inspection was conducted at Cheelcare's new 16,000 sq. ft. manufacturing and R&D facility in Markham, which the Company began occupying this fall as part of its broader
2025-11-24 7:00 AM EST | Cheelcare Inc.
Skye Bioscience to Participate in Upcoming Investment Conferences
San Diego, California--(Newsfile Corp. - November 24, 2025) - Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will participate in the following upcoming investment conferences: Citi Global Healthcare Conference (Miami) 1x1 meetings: Dec. 2 Evercore Annual Healthcare Conference (Coral Gables) Fireside Chat: Dec. 3, 12:55 pm
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-11-24 7:00 AM EST | Skye Bioscience, Inc.
Defence Therapeutics Announces Convertible Debenture Conversion
Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), announces that the holders of the Corporation's 8% convertible debentures issued on November 16, 2024 (the "Debentures") have converted all of the principal amount and the accrued interests thereof into an aggregate number of 2,607,600 common
Biotechnology, Pharmaceuticals, Health
2025-11-21 6:03 PM EST | Defence Therapeutics Inc.